You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Enhanced Treatment Management of Opioid-Dependence in an Office-Based Setting
SBC: MedicaSafe Inc Topic: NIDAPROJECT SUMMARY ABSTRACT Opioid use disorder is the leading cause of accidental death in the USwith overlethal drug overdoses inSAMHSA estimates thatmillion Americans misuse prescription opioids for non medical purposes annuallyPublic health officials and policymakers have acknowledged the urgent need for innovative approaches to the treatment of those with opioid use disorderin spite of thisthe a ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Tau oligomer platform validation using lead series candidate in htau mice
SBC: OLIGOMERIX INC Topic: NIATITLETau oligomer platform validation using lead series candidate in htau mice PROJECT SUMMARYSBIR Funding OpportunityAdvancing Research on Alzheimerandapos s DiseaseADand Alzheimerandapos s Disease Related DementiasADRDRRPASThe long term goal of this program is to develop a disease modifyingsmall molecule drug for Alzheimer s diseaseADand related tauopathiesThere is a critical unmet need for a di ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Gene and Stem Cell-Based Treatment for Tendinopathy
SBC: NEW YORK R & D CENTER FOR TRANSLATIONAL MEDICINE & THERAPEUTICS INC Topic: RProject SummaryTendinopathy is a common chronic tendon disorder that affectsof individuals overyears oldIt is characterized by painswellingloss of functionand impaired performanceThere is currently no cure for tendinopathySpontaneous repair or treatment typically leads to scar formationresulting in a weakened tissue with reduced function and mechanical properties that may ultimately rupture with f ...
SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Scale-up and Synthesis of a Tau Oligomer Inhibitor to initiate IND enabling studies for AD and ADRD
SBC: OLIGOMERIX INC Topic: NIAPROJECT SUMMARYSBIR RRFast Track ApplicationFOA NumberPASThe long term goal of this program is to develop a disease modifyingsmall molecule drug for Alzheimer s diseaseADand AD related dementiasADRDwith tau pathologyThere is a critical unmet need for a disease modifying drugDMDfor ADChronic treatment strategies require safeeffectiveand economically feasible approaches such as small molecule drugsT ...
SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Development and validation of therapy for mucopolysaccharidosis III
SBC: Phoenix Nest Inc. Topic: 103Project Summary Sanfilippo disease (mucopolysaccharidosis type III; MPS III) is a devastating neurodegenerative lysosomal storage disorder of childhood whose pathologic features are neurologic: slowing of development, severe behavioral problems, progressive cognitive decline, dementia, and decline in motor skills leading to immobility, unresponsiveness, and death. We have focused on MPS IIID cause ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
High-throughput nanoMEA-based Proarrhythmia Assay
SBC: CURI BIO, INC. Topic: NHLBIPROJECT SUMMARY Failure of new drugs at late stages of development is an extremely costly event commonly associated with the detection of unexpected arrhythmogenic properties in novel drugs Undetected arrhythmia inducing effects are also a common reason for drug withdrawal from the market As a result the FDA now mandates that all new drugs be tested for potential arrhythmogenic properties which ha ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Development of an advanced cryothermal ablation catheter and method for treating cardiac arrhythmias
SBC: CELL PRESERVATION SERVICES INC Topic: RThe need for the development of new strategies for treatment of cardiac arrhythmiasincluding ventricular arrhythmiashas experienced a palpable increase in the last few yearsVentricular ArrhythmiaVAor ventricular tachycardiaVTis a severe abnormal heart rhythm which can cause death if not treated immediatelyVentricular FibrillationVFis the most serious form of VAVF is most commonly caused by VT and ...
SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Preparation and development of a stabilized C3 analog for the treatment of paroxysmal nocturnal hemoglobinemia
SBC: Cascade Biotechnology Topic: NHLBIAbstract We propose to develop analogs of human complement Cthat have the ability to form a stable CconvertaseIn additionthese proteins will be designed to decrease the affinity of the proteins for factor H bindingAll proteins will be expressed in the Baculovirus insect protein expression systemand tested for their ability to form a stable Cconvertase enzyme that is able to deplete complement in h ...
SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Transforming STEM Education in K-12 using the Biological Interactive Outcomes Modular Environment (BIOME)
SBC: IQ Smart Interactive LLC Topic: 500PROJECT SUMMARYThe United States is falling behind in Science and Math according to results from the Programme for International Student AssessmentPISAranking the US asth in Science andth in Mathematics out ofcountriesThese unfortunate statistics could be attributed to teacher hesitations in teaching math and scienceinability to excite student interest in STEM subjectsor an unclear real world appl ...
SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Interstitial Intensity Modulated Photodynamic Therapy Phase II
SBC: SIMPHOTEK, INC. Topic: 102Photodynamic therapy (PDT) is a cancer treatment that utilizes visible or near-infrared light to activate a light- sensitive drug (photosensitizer, PS) that, in turn, creates reactive singlet oxygen species from ground triplet state oxygen that is present in the tumor. The resulting reactive products induce tissue death. Ideally the reactive species will be produced within only the target volume, ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health